AU2004263297A1 - Substituted imidazopyrimidines for the prevention and treatment of cancer - Google Patents

Substituted imidazopyrimidines for the prevention and treatment of cancer Download PDF

Info

Publication number
AU2004263297A1
AU2004263297A1 AU2004263297A AU2004263297A AU2004263297A1 AU 2004263297 A1 AU2004263297 A1 AU 2004263297A1 AU 2004263297 A AU2004263297 A AU 2004263297A AU 2004263297 A AU2004263297 A AU 2004263297A AU 2004263297 A1 AU2004263297 A1 AU 2004263297A1
Authority
AU
Australia
Prior art keywords
pyrimidine
imidazo
nmr
methylsulfanylphenyl
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004263297A
Other languages
English (en)
Inventor
Dolors Balsa Lopez
Juan Lorenzo Catena Ruiz
Carles Farrerons Gallemi
Andres Fernandez Garcia
Anna Fernandez Serrat
Carmen Lagunas Arnal
Carolina Salcedo Roca
Carmen Serra Comas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Salvat SA
Original Assignee
Laboratorios Salvat SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Salvat SA filed Critical Laboratorios Salvat SA
Publication of AU2004263297A1 publication Critical patent/AU2004263297A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2004263297A 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer Abandoned AU2004263297A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301906 2003-07-30
ES200301906 2003-07-30
PCT/EP2004/008476 WO2005014598A1 (en) 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer

Publications (1)

Publication Number Publication Date
AU2004263297A1 true AU2004263297A1 (en) 2005-02-17

Family

ID=34130555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004263297A Abandoned AU2004263297A1 (en) 2003-07-30 2004-07-29 Substituted imidazopyrimidines for the prevention and treatment of cancer

Country Status (14)

Country Link
US (1) US20060189631A1 (https=)
EP (1) EP1660500B1 (https=)
JP (1) JP2007500160A (https=)
KR (1) KR20060034303A (https=)
CN (1) CN1860121A (https=)
AT (1) ATE380816T1 (https=)
AU (1) AU2004263297A1 (https=)
BR (1) BRPI0412636A (https=)
CA (1) CA2534292A1 (https=)
DE (1) DE602004010680T2 (https=)
EA (1) EA009038B1 (https=)
ES (1) ES2298798T3 (https=)
WO (1) WO2005014598A1 (https=)
ZA (1) ZA200601706B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
EP2057164A1 (en) 2006-08-07 2009-05-13 Incyte Corporation Triazolotriazines as kinase inhibitors
RS54510B1 (sr) 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
WO2009021990A1 (en) * 2007-08-14 2009-02-19 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
TWI472529B (zh) 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
MX2012008898A (es) 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
CN102796103A (zh) * 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
BR112016014004B1 (pt) 2013-12-19 2022-11-01 Novartis Ag Compostos para tratamento de doenças parasíticas, seus usos, e composições farmacêuticas
CA2979342A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
WO2017193016A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.

Also Published As

Publication number Publication date
DE602004010680T2 (de) 2009-01-02
EP1660500A1 (en) 2006-05-31
ES2298798T3 (es) 2008-05-16
EA200600330A1 (ru) 2006-08-25
ATE380816T1 (de) 2007-12-15
WO2005014598A1 (en) 2005-02-17
DE602004010680D1 (de) 2008-01-24
BRPI0412636A (pt) 2006-09-26
KR20060034303A (ko) 2006-04-21
EA009038B1 (ru) 2007-10-26
JP2007500160A (ja) 2007-01-11
US20060189631A1 (en) 2006-08-24
ZA200601706B (en) 2007-09-26
EP1660500B1 (en) 2007-12-12
CN1860121A (zh) 2006-11-08
CA2534292A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
EP1660500B1 (en) Substituted imidazopyrimidines for the prevention and treatment of cancer
EP3860990B1 (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
CN103339134B (zh) 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
Abbas et al. Synthesis, antitumor and antibacterial activities of some novel tetrahydrobenzo [4, 5] thieno [2, 3-d] pyrimidine derivatives
TW201906848A (zh) 化學化合物
CN105164135A (zh) 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓
US6869956B2 (en) Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
WO2009143018A2 (en) Compounds and methods for kinase modulation, and indications therefor
KR20140014147A (ko) 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
CN102271515A (zh) 吡唑并嘧啶jak抑制剂化合物和方法
AU2002247059B2 (en) Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
JP2010222370A (ja) 二環式ピリミジノンおよびその使用
EP1325009B1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
CN102388055A (zh) 咪唑并[2,1-b][1,3,4]噻二唑衍生物
AU2002211827A1 (en) Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
WO2020079652A1 (en) Kinase inhibitors
CN102548995B (zh) 杂环腙化合物以及它们治疗癌症和炎症的用途
Keshari et al. Novel Mannich-bases as potential anticonvulsants: syntheses, characterization and biological evaluation
MXPA06001262A (en) Substituted imidazopyrimidines for the prevention and treatment of cancer
EP3958980A1 (en) Targeted novel triazolothiadiazine derivatives for the treatment of lung cancer
EP4701635A1 (en) 1,2,4-triazole-3-thione inhibitors of trex2 for use in the treatment of psoriasis, atopic dermatitis or ichthyosis
CA3114375C (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
Palusa et al. Synthesis and evaluation of a series of pyrimidine substituted 1, 3, 4-oxadiazole derivatives as antimicrobial and anti-inflammatory agents
KR20260014200A (ko) 신규한 이미다조피리딘 유도체 및 이의 용도
AU2007200555A1 (en) Methods of treating inflammatory and immune diseases using inhibitors of IKappaB kinase (IKK)

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application